Viking Therapeutics (VKTX) stock receives a Neutral rating at Goldman Sachs due to intense competition in its targeted ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide ... Lilly, meanwhile, is developing a triple receptor agonist, retatrutide, that targets GLP-1, GIP, and glucagon and is also in phase 3.

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly ... its portfolio also including an oral GLP-1 drug and a triple agonist therapy that could both be given the green light ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists ...